IDPH--Positive preliminary results for pivotal trial of ID Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IDPH--Positive preliminary results for pivotal trial of ID

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: I. Luttichuys who wrote (1031)	6/24/1997 1:32:00 PM
From: Rick Costantino	of 1762

Bennett and all, Yes, this is a momentary setback, but IDPH still has a lot to offer. (Any info on the other RA drug mentioned in the release which is in Phase II?) Actually, this is more of a setback for SmithKline, since IDEC has only "lost" future milestone and royalty payments while SK put up the cash for the trials. Anyway, I am primarily interested in anti C2B8, which should see approval this suummer, and the Yt derivatives which are in the wings. Also, don't forget that IDEC has an important patent covering primatization of MAbs. Rick C

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next